| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.12.10.1176 |
| P698 | PubMed publication ID | 1390589 |
| P2093 | author name string | J. D. Brunzell | |
| B. G. Brown | |||
| S. P. Babirak | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| hyperlipidemia | Q1079120 | ||
| familial combined hyperlipidemia | Q2242370 | ||
| P304 | page(s) | 1176-1183 | |
| P577 | publication date | 1992-10-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Familial combined hyperlipidemia and abnormal lipoprotein lipase | |
| P478 | volume | 12 |
| Q34386536 | A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia |
| Q34335556 | A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity |
| Q36727383 | A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma |
| Q44016842 | Activity and concentration of lipoprotein lipase in post-heparin plasma and the extent of coronary artery disease |
| Q30968588 | Atherogenesis and metabolic dysregulation in LDL receptor-knockout rats |
| Q34107183 | Common mutations of the lipoprotein lipase gene and their clinical significance |
| Q34452376 | Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. |
| Q37364446 | Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes |
| Q74127774 | Dyslipidemias associated with heterozygous lipoprotein lipase mutations in the French-Canadian population |
| Q47739407 | Evidence against alterations in Lecithin:cholesterol acyltransferase (LCAT) activity in familial combined hyperlipidemia. |
| Q72866557 | Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management |
| Q43245222 | Frequent detection of familial hypercholesterolemia mutations in familial combined hyperlipidemia |
| Q37116417 | Galanin preproprotein is associated with elevated plasma triglycerides |
| Q50874132 | Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. |
| Q34107190 | Genetics of familial combined hyperlipidemia |
| Q72566665 | Genotype at a major locus with large effects on apolipoprotein B levels predicts familial combined hyperlipidemia |
| Q35881830 | Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia |
| Q34011027 | Insulin resistance and cardiovascular disease |
| Q43631829 | Insulin resistance in the St. Thomas' mixed hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia |
| Q51538648 | Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. |
| Q33879523 | Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families |
| Q35212552 | Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia |
| Q61560715 | Lipoprotein lipase activity in patients with combined hyperlipidaemia |
| Q40964792 | Low-density lipoprotein heterogeneity |
| Q53959743 | Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. |
| Q73701461 | Phenotype expression in familial combined hyperlipidemia |
| Q47382029 | Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size |
| Q53938520 | Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. |
| Q44019597 | Reduced structural and functional skin capillaries in familial combined hyperlipidemia affected men, associated with increased remnant-like lipoprotein cholesterol levels |
| Q41731956 | Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia |
| Q35767590 | Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes |
| Q46908176 | The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia |
| Q41519599 | The acylation stimulating protein pathway: Clinical implications |
| Q34524296 | The effect of n-3 fatty acids on low density lipoprotein subfractions |
| Q40964824 | The genetic determinants of plasma cholesterol and response to diet |
| Q37983699 | The genetics of familial combined hyperlipidaemia |
| Q34974691 | The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion |
| Q41731965 | Use of niacin, statins, and resins in patients with combined hyperlipidemia. |
Search more.